The Mel Robbins PodcastHow to Balance Your Hormones: What Your Doctor Isn’t Telling You About Menopause
CHAPTERS
- 0:00 – 5:46
Menopause as “puberty in reverse”: what’s normal, what’s not
Mel and Dr. Jen Gunter reframe menopause as a predictable life stage—similar to puberty—rather than a sign that your body is “falling apart.” They normalize the wide range of experiences while emphasizing that “normal” doesn’t mean you must suffer without help.
- •Menopause transition is a physiologic change, not a personal failure
- •The “puberty in reverse” analogy helps explain the long, uneven transition
- •Symptoms vary widely; some people have minimal disruption, others struggle
- •Education reduces shame and the feeling of being ‘broken’
- 5:46 – 9:05
What’s happening hormonally in perimenopause (and how long it can last)
Dr. Gunter explains the menopause transition (perimenopause) as years of hormonal volatility, not a smooth decline. The discussion covers timing, irregular cycles, and why symptoms can feel chaotic and unpredictable.
- •Perimenopause typically lasts ~4–10 years
- •Follicle/ovulation decline drives fluctuating estrogen and progesterone
- •Cycles can become shorter/longer, heavier, or irregular; hormones can spike
- •The transition is ‘hormonal chaos,’ not a steady slope
- 9:05 – 10:39
Myths that keep women stuck: ‘life is over’ and ‘you’re going crazy’
They tackle cultural myths that menopause ends your vitality or makes you irrational. Mel highlights the relief that comes from having symptoms (brain fog, frozen shoulder, mood shifts) explained and validated.
- •Big myth: menopause means your best years are behind you
- •Validation and knowledge reduce fear and self-blame
- •Many symptoms cluster during the transition and are explainable
- •There are treatments available when symptoms are severe
- 10:39 – 12:39
Three high-impact non-hormonal foundations: exercise, fiber/protein, no smoking
Before diving into hormones, Dr. Gunter prioritizes lifestyle interventions that affect nearly every menopause-related health domain. Exercise is positioned as the single most powerful tool for long-term outcomes like bone, brain, and heart health.
- •Exercise is #1: supports bone, muscle, mood, brain, balance, heart
- •Resistance training matters for muscle mass and fall prevention
- •Nutrition targets: ~25g fiber/day; many women need more protein
- •Avoid smoking to reduce health risks that worsen with age
- 12:39 – 13:01
What menopausal hormone therapy (MHT/HRT) is—and the main legitimate types
Dr. Gunter defines menopausal hormone therapy and separates evidence-based, FDA-approved options from ‘scams.’ The focus is on safety: studied dosing, known absorption, and proven benefit for symptoms and osteoporosis prevention.
- •MHT treats menopause symptoms and can prevent osteoporosis in indicated cases
- •Core safety question: studied, effective, and reliably dosed
- •FDA-approved options include estradiol (common) and Premarin (CEE)
- •Delivery routes: transdermal (skin), oral, and vaginal
- 13:01 – 15:50
Why ‘bioidentical’ is a marketing term: compounded hormones vs FDA-approved therapy
This segment dismantles ‘bioidentical’ branding and clarifies that the hormone molecule is often the same—what differs is the rigor behind the delivery system. Mel shares her own experience with compounded products and how inconsistent dosing can be.
- •‘Bioidentical’ is medically meaningless; often used to sell compounded products
- •Plant-based/‘natural’ language is marketing, not a safety guarantee
- •Compounded products lack the studies that establish consistent absorption
- •Mel’s story illustrates storage/measurement issues and real-world inconsistency
- 15:50 – 18:37
What to ask your doctor: the package insert test and FDA approval signals
Dr. Gunter offers a practical way to tell if a product is FDA-approved: it comes with a package insert detailing risks/benefits. They explain how compounded products exploit loopholes, which can falsely make them look ‘safer’ because they lack warnings.
- •If there’s no folded package insert, it’s not FDA-approved
- •Compounded products don’t have required standardized risk disclosures
- •Lack of a black-box warning can reflect lack of oversight—not lower risk
- •Patients should prioritize measurable, regulated dosing and documentation
- 18:37 – 28:15
The compounded-hormone warning: quality control, dosing uncertainty, and when compounding is appropriate
Dr. Gunter explains why menopause societies don’t recommend compounded hormones and uses the ‘gas station vs roadside gas’ analogy. They also clarify the narrow, legitimate role for compounding—mainly true allergies or lack of commercial alternatives.
- •Major menopause organizations do not recommend compounded hormones
- •Key risks: too much estrogen, too little progesterone, or inadequate protection
- •FDA-approved meds are batch-tested; compounded products are not
- •Appropriate compounding example: peanut allergy to a specific formulation oil
- 28:15 – 29:29
The only estrogen terms many people need: estradiol vs Premarin—and why route matters
To simplify decision-making, Dr. Gunter recommends learning two estrogen categories and three delivery routes. The ‘first-line’ starting approach highlighted is transdermal estradiol, partly due to a lower blood-clot risk than oral estrogen.
- •Learn: estradiol (most common) and Premarin/CEE (from horse urine)
- •Learn routes: transdermal, transvaginal, oral
- •First-line starting option often: transdermal estradiol
- •Route influences clot risk; skin delivery is generally lower risk than oral
- 29:29 – 31:31
Mel shows her patch: correct placement, absorption differences, and vaginal estrogen options
Mel demonstrates her estradiol patch and Dr. Gunter explains why placement matters—because absorption varies by body location and has been studied in FDA-approved products. They also cover vaginal estrogen/rings for dryness, UTIs, and painful sex, including localized vs systemic options.
- •Use patches exactly as the package insert directs; location changes absorption
- •Patches can improve quality of life when symptoms respond
- •Vaginal estrogen can be localized or systemic depending on product
- •Vaginal therapy helps dryness, recurrent UTIs, and pain with sex
- 31:31 – 33:42
Pellets: what they are, why they’re controversial, and why symptom-based care beats level-chasing
Dr. Gunter describes pellet implants as compounded products with uncertain dosing and limited adverse-event reporting. She criticizes protocols that rely on frequent hormone-level testing and ‘proprietary’ re-dosing schedules rather than symptom response and evidence-based guidelines.
- •Pellets are implanted compounded hormones; dosing and batch-testing are unclear
- •Can lead to very high hormone levels and unpredictable drop-offs
- •Adverse events may be underreported compared with regulated products
- •Hormone therapy is typically guided by symptoms, not routine level monitoring
- 33:42 – 37:38
Do you need hormone blood tests? Age thresholds, missed periods, and the ‘timing’ of starting estrogen
They clarify when bloodwork is and isn’t needed, emphasizing that typical symptoms after 45 don’t require testing to start therapy. Dr. Gunter also introduces timing considerations: starting estrogen much later (over 60 or >10 years since last period) raises certain risks.
- •If ≥45 with typical symptoms, blood tests usually aren’t needed to begin MHT
- •If <45 with skipped periods, evaluate with labs to rule out other causes
- •Average menopause age is ~51; typical onset of transition around mid-40s
- •Avoid starting estrogen >60 or >10 years past last period due to higher risks
- 37:38 – 45:43
Breast cancer fears and the WHI study: what it found, what changed, and how risk is individualized
Mel raises lingering fear from the Women’s Health Initiative, and Dr. Gunter explains how early communication amplified alarm. They discuss how today’s commonly used regimens differ and how risk-benefit decisions should be personalized using cardiovascular and breast cancer risk tools.
- •WHI was large and influential; early press communication fueled fear
- •Risk varies by regimen (estrogen + certain progestins vs other approaches)
- •Transdermal estrogen is often favored when clot/cardiovascular risk is a concern
- •Use risk calculators (ASCVD, breast cancer risk tools) to guide decisions
- 45:43 – 50:17
How to know if HRT is working: timeline, ‘green vs yellow light’ indications, and the dose-escalation mistake
Dr. Gunter explains that symptom improvement—often within weeks for hot flashes—is the main indicator of effectiveness, while prevention goals (like bone health) require reliable dosing. She distinguishes strong indications from less-proven uses (e.g., joint pain, brain fog) and warns against endlessly increasing estrogen dose when benefits aren’t appearing.
- •Hot flashes often improve within ~4 weeks; depression may improve in months
- •Strong indications: vasomotor symptoms, osteoporosis prevention; early menopause needs treatment to average menopause age
- •Less certain: joint pain, brain fog; consider sleep and depression as contributors
- •Caution: avoid unchecked dose escalation; reassess if needing very high doses
- 50:17 – 1:06:01
Relationships, support, and accountability: ‘don’t use menopause to excuse mediocre men’
They address how menopause can be weaponized to dismiss women’s valid frustration in relationships and at work. Dr. Gunter argues that mistreatment isn’t a hormone problem, then offers practical guidance for partners/families to learn, listen, and share household labor more equitably.
- •Menopause shouldn’t be used to gaslight women about legitimate grievances
- •Support means education, listening, and tangible help with chores/labor
- •Workplace accommodations matter—but shouldn’t replace equity and advancement
- •Partners can attend appointments, help track information, and reduce stress
